Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in coming days, analysts and especially investors will keep their eyes on whether the ...

Beam Therapeutics recently announced that its BEAM-302 program received FDA orphan drug designation, alongside encouraging updates for its gene-editing therapies targeting rare diseases such as sickle ...

Biotech company Metagenomi (NASDAQ:MGX) is utilizing artificial intelligence chips from Amazon Web Services (AMZN) to enhance ...

Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...

Amazon ($AMZN) has come out on top of rivals such as Nvidia ($NVDA) when it comes to utilizing AI to fight diseases. However, ...

Vertex Pharmaceuticals recently announced important updates on its investigational kidney disease therapy povetacicept, including FDA regulatory progress and upcoming data presentations, as well as ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a ...

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Chardan 9 th Annual Genetic Medicines ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: 4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA) ...